NIH-funded analysis estimates effective PrEP dosing

Findings apply only to men who have sex with men

2012-09-13

(Press-News.org) WHAT: Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP. The level of protection, however, depends on taking the drugs regularly. For instance, the landmark iPrEx study (http://www.niaid.nih.gov/news/newsreleases/2010/Pages/iPrEx.aspx) found that overall, men who have sex with men who received a daily dose of tenofovir plus emtricitabine (Truvada) had a 44 percent lower risk of HIV infection compared with those who received a daily placebo pill. But for the subset of participants who had detectable drug in their blood—indicating that they were actually taking Truvada regularly—the risk of HIV infection was 92 percent less than for the placebo group.

Led by study chair Robert M. Grant, M.D., of the Gladstone Institute of Virology and Immunology, the iPrEx team recently set out to estimate what drug concentration in blood cells was associated with a 90 percent reduction in HIV infection risk, and how many Truvada doses per week would achieve that concentration. The research was funded by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health, the National Center for Research Resources and the National Center for Advancing Translational Sciences, all part of the National Institutes of Health.

The scientists examined data from the iPrEx study to determine the concentrations of tenofovir diphosphate, the active form of tenofovir, associated with different levels of protection from HIV acquisition. They focused on tenofovir diphosphate because it is believed to be the most important component of Truvada for PrEP. The researchers also conducted a small study to determine the blood concentrations of tenofovir diphosphate that resulted from taking a Truvada pill 2, 4 and 7 days per week. Through their analyses, the scientists found that to achieve the 90 percent risk reduction in HIV acquisition, participants needed to take Truvada at least 4 days per week (which would achieve a concentration of roughly 16 x 10-15 moles of tenofovir diphosphate per million blood cells). The researchers also estimated that taking Truvada daily would lead to a 99 percent reduction in HIV infection risk.

The authors caution that the findings of this study, which are relevant to men who have sex with men (the iPrEx study population), may not be applicable to other populations, such as heterosexuals. This is because the minimum protective drug concentration in the blood and the number of tablets per week required to achieve that concentration in target tissues may differ depending on the route and frequency of exposure to HIV.

### This study was funded by NIH grants R21 MH085598, UO1 AI084735, RO1 AI062333, UO1 AI064002 and UL1 RR024131.

ARTICLE: Anderson et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science Translational Medicine. DOI: 10.1126/scitranslmed.3004006 (2012).

WHO: NIAID Director Anthony S. Fauci, M.D., and Carl W. Dieffenbach, Ph.D., director of the NIAID Division of AIDS, are available for interviews.

CONTACT: To schedule interviews, please contact Laura S. Leifman, (301) 402-1663, sivitzl@niaid.nih.gov.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

NIH...Turning Discovery Into Health

ELSE PRESS RELEASES FROM THIS DATE:

Cell death mystery yields new suspect for cancer drug development

2012-09-13

A mysterious form of cell death, coded in proteins and enzymes, led to a discovery by UNC researchers uncovering a prime suspect for new cancer drug development. CIB1 is a protein discovered in the lab of Leslie Parise, PhD , professor and chair of the department of biochemistry at the University of North Carolina at Chapel Hill. The small calcium binding protein is found in all kinds of cells. Cassandra Moran, DO, was a pediatric oncology fellow at UNC prior to accepting a faculty position at Duke University. She is interested in neuroblastoma, a deadly form of ...

Computer program can identify rough sketches

2012-09-13

VIDEO: To develop a program that allows computers to recognize rough sketches, we need to understand how humans actually sketch objects. Researchers from Brown University and the Technical University of Berlin... Click here for more information. PROVIDENCE, R.I. [Brown University] — First they took over chess. Then Jeopardy. Soon, computers could make the ideal partner in a game of Draw Something (or its forebear, Pictionary). Researchers from Brown University and the ...

Effects of stopping alcohol consumption on subsequent risk of esophageal cancer

2012-09-13

Cancer of the oesophagus is becoming more common in Europe and North America. Around 7,800 people in the UK are diagnosed each year. The exact causes of this cancer aren't fully understood. It appears to be more common in people who have long-term acid reflux (backflow of stomach acid into the oesophagus). Other factors that can affect the risk of developing cancer of the oesophagus include: Gender – It is more common in men than in women. Age – The risk of developing oesophageal cancer increases as we get older. It occurs most commonly in people over 45. Smoking ...

U-M guidelines help family physicians evaluate, manage urinary incontinence for women

2012-09-13

ANN ARBOR, Mich. — Millions of women experience a loss of bladder control, or urinary incontinence, in their lifetime. It's a common and often embarrassing problem that many patients don't bring up with their doctors – and when they do, it may be mentioned as a casual side note during a visit for more pressing medical issues. Now, new guidelines from doctors at the University of Michigan Health System offer family physicians a step-by-step guide for the evaluation of urinary leakage, to prevent this quality-of-life issue from being ignored. "I think a lot of physicians ...

Parental divorce linked to stroke in males

2012-09-13

TORONTO, ON – Men with divorced parents are significantly more likely to suffer a stroke than men from intact families, shows a new study from the University of Toronto. The study, to be published this month in the International Journal of Stroke, shows that adult men who had experienced parental divorce before they turned 18 are three times more likely to suffer a stroke than men whose parents did not divorce. Women from divorced families did not have a higher risk of stroke than women from intact families. "The strong association we found for males between parental ...

Lack of oxygen in cancer cells leads to growth and metastasis

2012-09-13

It seems as if a tumor deprived of oxygen would shrink. However, numerous studies have shown that tumor hypoxia, in which portions of the tumor have significantly low oxygen concentrations, is in fact linked with more aggressive tumor behavior and poorer prognosis. It's as if rather than succumbing to gently hypoxic conditions, the lack of oxygen commonly created as a tumor outgrows its blood supply signals a tumor to grow and metastasize in search of new oxygen sources – for example, hypoxic bladder cancers are likely to metastasize to the lungs, which is frequently deadly. ...

Laser-powered 'needle' promises pain-free injections

2012-09-13

VIDEO: The movie shows the injector firing into open air without a skin or gel target. The jet, which is approximately the diameter of a human hair, seems dispersed but a... Click here for more information. WASHINGTON, Sept. 13—From annual flu shots to childhood immunizations, needle injections are among the least popular staples of medical care. Though various techniques have been developed in hopes of taking the "ouch" out of injections, hypodermic needles are still the ...

IU chemist develops new synthesis of most useful, yet expensive, antimalarial drug

2012-09-13

BLOOMINGTON, Ind. -- In 2010 malaria caused an estimated 665,000 deaths, mostly among African children. Now, chemists at Indiana University have developed a new synthesis for the world's most useful antimalarial drug, artemisinin, giving hope that fully synthetic artemisinin might help reduce the cost of the live-saving drug in the future. Effective deployment of ACT, or artemisinin-based combination therapy, has been slow due to high production costs of artemisinin. The World Health Organization has set a target "per gram" cost for artemisinin of 25 cents or less, but ...

Study of giant viruses shakes up tree of life

2012-09-13

CHAMPAIGN, Ill. — A new study of giant viruses supports the idea that viruses are ancient living organisms and not inanimate molecular remnants run amok, as some scientists have argued. The study reshapes the universal family tree, adding a fourth major branch to the three that most scientists agree represent the fundamental domains of life. The new findings appear in the journal BMC Evolutionary Biology. The researchers used a relatively new method to peer into the distant past. Rather than comparing genetic sequences, which are unstable and change rapidly over time, ...

Scientists use sound waves to levitate liquids, improve pharmaceuticals

2012-09-13

It's not a magic trick and it's not sleight of hand – scientists really are using levitation to improve the drug development process, eventually yielding more effective pharmaceuticals with fewer side effects. Scientists at the U.S. Department of Energy's (DOE) Argonne National Laboratory have discovered a way to use sound waves to levitate individual droplets of solutions containing different pharmaceuticals. While the connection between levitation and drug development may not be immediately apparent, a special relationship emerges at the molecular level. At the molecular ...

NIH-funded analysis estimates effective PrEP dosing

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: